Author index

van Aalst-Cohen, E.S. *see* Rana, J.S.
Aasa, M. *see* Jensen, J.
Abildgaard, U. *see* Njaastad, A.M.
Abou-Raya, A. *see* Abou-Raya, S.
Abou-Raya, S. & Abou-Raya, A. Spinal tuberculosis: overlooked?, 160
Adami, H.-O. *see* Dickman, P.W.
Adami, H.-O. *see* Lu, M.
Agarwal, A.K., Silver, M.R., Reed, J.E., Dhingra, R.K., Liu, W., Varma, N. & Stehman-Breen, C. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis, 577
Allemann, S. *see* Stettler, C.
Almquist, T., Forslund, L., Rehnqvist, N. & Hjemdahl, P. Prognostic implications of renal dysfunction in patients with stable angina pectoris, 537
Andersson, C. *see* Norberg, M.
Angelin, B. *see* Lundåsen, T.
Ängquist, K.-A. *see* Herlitz, J.
Asakawa, A. *see* Inui, T.
Asplund, K. *see* Claesson, M.
Attvall, S. *see* Smith, U.
Avogaro, A. *see* Cesari, M.

Bauer, T.T., Ewig, S., Marre, R., Suttorp, N., Welte, T. & The Capnetz Study Group. CRB-65 predicts death from community-acquired pneumonia, 93
Behre, C.J., Brohall, G., Hulthe, J., Wikstrand, J. & Fagerberg, B. Are serum adiponectin concentrations in a population sample of 64-year-old Caucasian women with varying glucose tolerance associated with ultrasound-assessed atherosclerosis?, 238
Berg, G. *see* Milakovic, M.
Bergfeldt, L. *see* Tabrizi, F.
Berglund, G. *see* Nilsson, P.M.
Bergmann, J.-F. *see* Bosson, J.-L.
Bergmann, A. *see* Müller, B.
Bergmann, J.F. *see* Fontaine, A.
Bhalla, A. *see* Singh, V.
Bingisser, R. *see* Müller, B.
Birgander, L.S. *see* Claesson, M.
Björkhem, I. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain, 493
Blanco, M. *see* Leira, R.
Blumstein, N.M. *see* Krüger, S.
de Boer, H. *see* Timmers, H.J.L.M.
Borén, J. *see* Smith, U.
Borro, P. *see* Testa, R.
Bosson, J.-L., Pouchain, D. & Bergmann, J.-F. for The ETAPE Study Group. A prospective observational study of a cohort of outpatients with anacute medical event and reduced mobility: incidence of symptomatic thromboembolism and description of thromboprophylaxispractices, 168
Botker, H.E. *see* Norrelund, H.
Breidthardt, T. *see* Mueller, C.
Brohall, G. *see* Behre, C.J.
Broliden, K., Tolfvenstam, T. & Norbeck, O. Clinical aspects of parvovirus B19 infection, 285
Buck, A.K. *see* Krüger, S.
Büller, H.R. *see* Kruip, M.J.H.A.
Burell, G. *see* Claesson, M.

Castellanos, M. *see* Leira, R.
Castillo, J. *see* Leira, R.
Ceppa, P. *see* Testa, R.
Cesari, M., Pessina, A.C., Zanchetta, M., De Toni, R., Avogaro, A., Pedon, L., Dorigatti, F., Maiolino, G. & Rossi, G.P. Low plasma adiponectin is associated with coronary artery disease but not with hypertension in high-risk nondiabetic patients, 474
Chandler, J. *see* Lips, P.
Chang, W.-Y. *see* Huang, J.-F.
Chen, S.-C. *see* Huang, J.-F.
Christ, E.R. *see* Stettler, C.
Christ, M. *see* Mueller, C.
Christ-Crain, M. *see* Müller, B.
Christiansen, J.S. *see* Nørrelund, H.
Chuang, W.-L. *see* Huang, J.-F.
Claesson, M., Birgander, L.S., Jansson, J.-H., Lindahl, B., Burell, G., Asplund, K. & Mattsson, C. Cognitive-behavioural stress management does not improve biological cardiovascular risk indicators in women with ischaemicheart disease: a randomized-controlled trial, 320
Cleland, J.G.F. *see* Loh, P.H.
Cohen, P. *see* Fontaine, A.
Coleman, C.I. *see* Henyan, N.N.
Csernok, E. *see* Lamprecht, P.

Dai, C.-Y. *see* Huang, J.-F.
Dávalos, A. *see* Leira, R.
De Toni, R. *see* Cesari, M.
Dhingra, R.K. *see* Agarwal, A.K.
Dhote, R. *see* Fontaine, A.
Dickman, P.W. & Adami, H.-O. Interpreting trends in cancer patient survival, 103
Diem, P. *see* Stettler, C.
Dorigatti, F. *see* Cesari, M.
Dorkhan, M., Magnusson, M., Frid, A., Grubb, A., Groop, L. & Jovinge, S. Glycaemic and nonglycaemic effects of pioglitazone in triple oraltherapy of patients with type 2 diabetes, 125
Drevs, J. & Schneider, V. The use of vascular biomarkers and imaging studies in the early clinical development of antitumour agents targeting angiogenesis, 517

Eggertsen, R. *see* Milakovic, M.
Eliasson, B. *see* Smith, U.
Eliasson, M., Janlert, U., Jansson, J.-H. & Stegmayr, B. Time trends in population cholesterol levels 1986–2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study, 551
Engdahl, J. *see* Herlitz, J.
Englund, A. *see* Tabrizi, F.
Engström, G., Hedblad, B. & Janzon, L. Reduced lung function predicts increased fatality in future cardiac events. A population-based study, 560
Erikssen, J. *see* Stavem, K.
Eriksson, J.W. *see* Norberg, M.
Ernst, E. & Pittler, M.H. Efficacy or effectiveness?, 488
Etminan, M. *see* Wiens, M.
Ewig, S. *see* Bauer, T.T.

Fadeel, B. *see* Wästfelt, M.
Fagerberg, B. *see* Behre, C.J.
Fiessinger, J.N. *see* Fontaine, A.
Figenschau, Y. *see* Iqbal, A.
Filippatos, G.S., Gavrielatos, G. & Kremastinos, D.T. Gains and losses during anticoagulation treatment in patients with mechanical heart valves., 595
Fišer, I. *see* Marschang, P.

© 2006 Blackwell Publishing Ltd

Flyvbjerg, A. *see* Nørrelund, H.
Fontaine, A., Mahé, I., Bergmann, J.F., Fiessinger, J.N., Dhote, R., Cohen, P. & Vinceneux, P. Effectiveness of written guidelines on the appropriateness of thromboprophylaxis prescriptions for medical patients: a prospective randomized study, 369
Foreyt, J.P. *see* Poston, W.S.C.
Forslund, L. *see* Almquist, T.
Frid, A. *see* Dorkhan, M.
Frystyk, J. *see* Nørrelund, H.

Gälman, C. *see* Lundåsen, T.
Gavrielatos, G. *see* Filippatos, G.S.
Gerardin, E. *see* Marie, I.
Giannini, E. *see* Testa, R.
Gill, S.S. *see* Wiens, M.
Gillespie, E.L. *see* Henyan, N.N.
Giscombe, R., Wang, X.B., Kakoulidou, M. & Lefvert, A.K. Characterization of the expanded T-cell populations in patients with Wegener's granulomatosis, 224
Groop, L. *see* Dorkhan, M.
Gross, W.L. *see* Lamprecht, P.
Grubb, A. *see* Dorkhan, M.

Haddock, C.K. *see* Poston, W.S.C.
Halbirk, M. *see* Nørrelund, H.
Halkes, S.J.M. *see* Kruip, M.J.H.A.
Hamdy, N.A.T. *see* Timmers, H.J.L.M.
Hammarström, L. *see* Norrby-Teglund, A.
Hansen, J.F. *see* Sajadieh, A.
Hansson, M. *see* Milakovic, M.
Haque, K.N. *see* Norrby-Teglund, A.
Hedblad, B. *see* Engström, G.
Heeney, J.L. Zoonotic viral diseases and the frontier of early diagnosis, control and prevention, 399
Hein, H.O. *see* Sajadieh, A.
Henter, J.-I. *see* Wästfelt, M.
Henyan, N.N., White, C.M., Gillespie, E.L., Smith, K., Coleman, C.I. & Kluger, J. The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death, 467
Herlitz, J., Svensson, L., Silfverstolpe, J., Ängquist, K.-A., Wisten, A., Engdahl, J. & Holmberg, S. Characteristics and outcome amongst young adults suffering from out-of-hospital cardiac arrest in whom cardiopulmonary resuscitation is attempted, 435
Hermus, A.R.M.M. *see* Timmers, H.J.L.M.
Hervé, F. *see* Marie, I.
Hishikawa, Y. *see* Inui, T.
Hjemdahl, P. *see* Almquist, T.
Ho, C.-K. *see* Huang, J.-F.
Hochholzer, W. *see* Mueller, C.
Holmberg, S. *see* Herlitz, J.
Hombach, V. *see* Krüger, S.
Hörkkö, S. *see* Pöykkö, S.M.
Hosking, D. *see* Lips, P.
Huang, J.-F., Chuang, W.-L., Dai, C.-Y., Ho, C.-K., Hwang, S.-J., Chen, S.-C., Lin, Z.-Y., Wang, L.-Y., Chang, W.-Y. & Yu, M.-L. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link?, 255
Huisman, M.V. *see* Kruip, M.J.H.A.
Hulthe, J. *see* Behre, C.J.
Hwang, S.-J. *see* Huang, J.-F.

Inui, A. *see* Inui, T.
Inui, T., Asakawa, A., Morita, Y., Mizuno, S., Natori, T., Kawaguchi, A., Murakami, M., Hishikawa, Y. & Inui, A. HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer, 484
Iqbal, A., Jorde, R. & Figenschau, Y. Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromsø Study, 53
Ishikawa, H. *see* Satoh, H.
Isola, L. *see* Testa, R.
Iyemere, V.P., Proudfoot, D., Weissberg, P.L. & Shanahan, C.M. Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification, 192

Janlert, U. *see* Eliasson, M.
Jansen, A.C. *see* Rana, J.S.
Jansson, J.-H. *see* Claesson, M.
Jansson, J.-H. *see* Eliasson, M.
Janzon, L. *see* Engström, G.
Jensen, J., Lagerqvist, B., Aasa, M., Särev, T., Nilsson, T. & Tornvall, P. Clinical and angiographic follow-up after coronary drug-eluting andbare metal stent implantation. Do drug-eluting stents hold thepromise?, 118
Jensen, J.S. *see* Klausen, K.P.
Johnsen, S.P. *see* Nakagawa, S.
Jones, P. *see* Poston, W.S.C.
Jorde, R. *see* Iqbal, A.
Jørgensen, J.O.L. *see* Nørrelund, H.
Jovinge, S. *see* Dorkhan, M.
Jukema, J.W. *see* Rana, J.S.

Kakoulidou, M. *see* Giscombe, R.
Karakoc, N. *see* Poston, W.S.C.
Karperien, M. *see* Timmers, H.J.L.M.
Kastelein, J.J.P. *see* Rana, J.S.
Kauma, H. *see* Pöykkö, S.M.
Kawaguchi, A. *see* Inui, T.
Kellokoski, E. *see* Pöykkö, S.M.
Kesäniemi, Y.A. *see* Pöykkö, S.M.
Klausen, K.P., Scharling, H. & Jensen, J.S. Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases, 231
Klima, T. *see* Mueller, C.
Kluger, J. *see* Henyan, N.N.
Kramer, M.H.H. *see* Kruip, M.J.H.A.
Kremastinos, D.T. *see* Filippatos, G.S.
Kropf, C. *see* Krüger, S.
Krüger, S., Buck, A.K., Blumstein, N.M., Pauls, S., Schelzig, H., Kropf, C., Schumann, C., Mottaghy, F.M., Hombach, V. & Reske, S.N. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours, 545
Kruip, M.J.H.A., Söhne, M., Nijkeuter, M., Kwakkel-van Erp, H.M., Tick, L.W., Halkes, S.J.M., Prins, M.H., Kramer, M.H.H., Huisman, M.V., Büller, H.R. & Leebeek, F.W.G. on behalf of the Christopher study investigators. A simple diagnostic strategy in hospitalized patients with clinically suspected pulmonary embolism, 459
Kujala, S. *see* Virkkunen, I.
Kumar, B. *see* Singh, V.
Kurishima, K. *see* Satoh, H.
Kvas, E. *see* Marschang, P.
Kwakkel-van Erp, H.M. *see* Kruip, M.J.H.A.

Laakso, M. *see* Smith, U.
Lagerqvist, B. *see* Jensen, J.
Lagerqvist, B. *see* Tornvall, P.
Lahaxe, L. *see* Marie, I.
Lamprecht, P., Csernok, E. & Gross, W.L. Effector memory T cells as driving force of granuloma formation and autoimmunity in Wegener's granulomatosis, 187
Lantieri, P.B. *see* Testa, R.

Larsson, A. *see* Milakovic, M.
Laule-Kilian, K. *see* Mueller, C.
Leebeek, F.W.G. *see* Kruip, M.J.H.A.
Lefvert, A.K. *see* Giscombe, R.
Leira, R., Rodríguez-Yáñez, M., Castellanos, M., Blanco, M., Nombela, F., Sobrino, T., Lizasoain, I., Dávalos, A. & Castillo, J. Hyperthermia is a surrogate marker of inflammation-mediated cause of brain damage in acute ischaemic stroke, 343
Levesque, H. *see* Marie, I.
Lin, Z.-Y. *see* Huang, J.-F.
Lind, L. *see* Ström Möller, C.
Lindahl, B. *see* Claesson, M.
Lindahl, B. *see* Norberg, M.
Lippuner, K. *see* Lips, P.
Lips, P., Hosking, D., Lippuner, K., Norquist, J.M., Wehren, L.E., Maalouf, G., Ragi-Eis, S. & Chandler, J. The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation, 245
Liu, W. *see* Agarwal, A.K.
Lizasoain, I. *see* Leira, R.
Loh, P.H., Rigby, A.S. & Cleland, J.G.F. Randomized trials are also essential for device therapy: reply, 282
Lu, M., Ye, W., Adami, H.-O. & Weiderpass, E. Prospective study of body size and risk for stroke amongst women below age 60, 442
Lundåsen, T., Gälman, C., Angelin, B. & Rudling, M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man, 530

Maalouf, G. *see* Lips, P.
Magnusson, M. *see* Dorkhan, M.
Mahé, I. *see* Fontaine, A.
Maiolino, G. *see* Cesari, M.
Marie, I., Hervé, F., Lahaxe, L., Robaday, S., Gerardin, E. & Levesque, H. Intravenous immunoglobulin-associated cranial pachymeningitis, 164
Marre, R. *see* Bauer, T.T.
Marschang, P., Sandhofer, A., Ritsch, A., Fis$^{\text{Ä}}$er, I., Kvas, E. & Patsch, J.R. Plasma cholesteryl ester transfer protein concentrations predictcardiovascular events in patients with coronary artery diseasetreatedwith pravastatin, 151
Mascitelli, L. & Pezzetta, F. Statin treatment, reduced T-cell content of atherosclerotic plaques and cancer, 592
Mattsson, C. *see* Claesson, M.
Milakovic, M., Berg, G., Eggertsen, R., Nyström, E., Olsson, A., Larsson, A. & Hansson, M. Determination of intrathyroidal iodine by X-ray fluorescence analysis in 60- to 65-year olds living in an iodine-sufficient area, 69
Milazzo, S. *see* Testa, R.
Mizuno, S. *see* Inui, T.
Møller, N. *see* Nørrelund, H.
Morgenthaler, N.G. *see* Müller, B.
Morita, Y. *see* Inui, T.
Mortensen, P.B. *see* Nakagawa, S.
Mosekilde, L. *see* Vestergaard, P.
Mottaghy, F.M. *see* Krüger, S.
Mueller, C., Laule-Kilian, K., Klima, T., Breidthardt, T., Hochholzer, W., Perruchoud, A.P. & Christ, M. Right bundle branch block and long-term mortality in patients with acute congestive heart failure, 421
Müller, B., Süess, E., Schuetz, P., Müller, C., Bingisser, R., Bergmann, A., Stolz, D., Tamm, M., Morgenthaler, N.G. & Christ-Crain, M. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections, 568
Müller, C. *see* Müller, B.
Murakami, M. *see* Inui, T.

Nain, C.K. *see* Singh, V.
Nakagawa, S., Pedersen, L., Olsen, M.L., Mortensen, P.B., Sørensen, H.T. & Johnsen, S.P. Antipsychotics and risk of first-time hospitalization for myocardial infarction: a population-based case-control study, 451
Natori, T. *see* Inui, T.
Nielsen, O.W. *see* Sajadieh, A.
Nijkeuter, M. *see* Kruip, M.J.H.A.
Nilsson, J.-Å. *see* Nilsson, P.M.
Nilsson, P.M., Nilsson, J.-Å. & Berglund, G. Population-attributable risk of coronary heart disease risk factorsduring long-term follow-up: the Malmö Preventive Project, 134
Nilsson, T. *see* Jensen, J.
Nilsson, T. *see* Tornvall, P.
Njaastad, A.M. & Abildgaard, U. Bleeding in patients with mechanical heart valves on warfarin: impact of target INR and of comorbidity, 596
Nombela, F. *see* Leira, R.
Norbeck, O. *see* Broliden, K.
Norberg, M., Eriksson, J.W., Lindahl, B., Andersson, C., Rolandsson, O., Stenlund, H. & Weinehall, L. A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed, 263
Norquist, J.M. *see* Lips, P.
Norrby-Teglund, A., Haque, K.N. & Hammarström, L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis, 509
Nørrelund, H., Wiggers, H., Halbirk, M., Frystyk, J., Flyvbjerg, A., Bøtker, H.E., Schmitz, O., Jørgensen, J.O.L., Christiansen, J.S. & Møller, N. Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure, 11
Nyström, E. *see* Milakovic, M.

Ohtsuka, M. *see* Satoh, H.
Olsen, M.L. *see* Nakagawa, S.
Olsson, A. *see* Milakovic, M.
Osswald, S. *see* Schaer, B.A.

Pace, P. *see* Poston, W.S.C.
Päivänsalo, M. *see* Pöykkö, S.M.
Patsch, J.R. *see* Marschang, P.
Pauls, S. *see* Krüger, S.
Pedersen, L. *see* Nakagawa, S.
Pedon, L. *see* Cesari, M.
Perruchoud, A.P. *see* Mueller, C.
Pessina, A.C. *see* Cesari, M.
Pettilä, V. *see* Saukkonen, K.A.
Pettilä, V. *see* Virkkunen, I.
Pezzetta, F. *see* Mascitelli, L.
Pinkston, M.M. *see* Poston, W.S.C.
Pittler, M.H. *see* Ernst, E.
Poston, W.S.C., Haddock, C.K., Pinkston, M.M., Pace, P., Reeves, R.S., Karakoc, N., Jones, P. & Foreyt, J.P. Evaluation of a primary care-oriented brief counselling interventionfor obesity with and without orlistat, 388
Pouchain, D. *see* Bosson, J.-L.
Pöykkö, S.M., Kellokoski, E., Ukkola, O., Kauma, H., Päivänsalo, M., Kesäniemi, Y.A. & Hörkkö, S. Plasma ghrelin concentrations are positively associated with carotid artery atherosclerosis in males, 43
Prins, M.H. *see* Kruip, M.J.H.A.
Proudfoot, D. *see* Iyemere, V.P.

Ragi-Eis, S. *see* Lips, P.
Rana, J.S., Jansen, A.C., Zwinderman, A.H., van Aalst-Cohen, E.S., Jukema, J.W., Trip, M.D. & Kastelein, J.J.P. Lipoprotein (a) and risk of cardiovascular disease in patients withmetabolic syndrome in a population of familial hypercholesterolaemia, 183
Räsänen, P. *see* Saukkonen, K.A.
Rasmussen, V. *see* Sajadieh, A.
Reed, J.E. *see* Agarwal, A.K.
Reeves, R.S. *see* Poston, W.S.C.
Rehnqvist, N. *see* Almquist, T.
Rejnmark, L. *see* Vestergaard, P.
Reske, S.N. *see* Krüger, S.
Rigby, A.S. *see* Loh, P.H.
Risso, D. *see* Testa, R.
Ritsch, A. *see* Marschang, P.
Robaday, S. *see* Marie, I.
Rodríguez-Yáñez, M. *see* Leira, R.
Roine, R.P. *see* Saukkonen, K.A.
Rolandsson, O. *see* Norberg, M.
Rosenqvist, M. *see* Tabrizi, F.
Rossi, G.P. *see* Cesari, M.
Rück, A. & Sylvén, C. Randomized trials are also essential for device therapy, 281
Rudling, M. *see* Lundåsen, T.
Ryynänen, S. *see* Virkkunen, I.

Sajadieh, A., Nielsen, O.W., Rasmussen, V., Hein, H.O. & Hansen, J.F. C-reactive protein, heart rate variability and prognosis in community subjects with no apparent heart disease, 377
Sandhofer, A. *see* Marschang, P.
Sandvik, L. *see* Stavem, K.
Särev, T. *see* Jensen, J.
Satoh, H., Kurishima, K., Ishikawa, H. & Ohtsuka, M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases, 429
Saukkonen, K.A., Varpula, M., Räsänen, P., Roine, R.P., Voipio-Pulkki, L.-M. & Pettilä, V. The effect of emergency department delay on outcome in critically ill medical patients: evaluation using hospital mortality and quality of life at 6 months, 586
Schaer, B.A., Sticherling, C. & Osswald, S. What are the professional and logistic demands to appropriately follow patients with an implantable cardioverter-defibrillator?, 88
Scharling, H. *see* Klausen, K.P.
Schelzig, H. *see* Krüger, S.
Schmitz, O. *see* Norrelund, H.
Schneider, V. *see* Drevs, J.
Schuetz, P. *see* Müller, B.
Schumann, C. *see* Krüger, S.
Shanahan, C.M. *see* Iyemere, V.P.
Sharma, A.K. *see* Singh, V.
Sharma, N. *see* Singh, V.
Shepherd, J. Who should receive a statin these days? Lessons from recent clinical trials, 305
Silfvast, T. *see* Virkkunen, I.
Silfverstolpe, J. *see* Herlitz, J.
Silver, M.R. *see* Agarwal, A.K.
Singh, B. *see* Singh, V.
Singh, V., Kumar, B., Nain, C.K., Singh, B., Sharma, N., Bhalla, A. & Sharma, A.K. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study, 62
Smith, K. *see* Henyan, N.N.
Smith, U., Laakso, M., Eliasson, B., Wesslau, C., Borén, J., Wiklund, O. & Attvall, S. Pathogenesis and treatment of diabetic vascular disease – illustrated by two cases, 409
Sobrino, T. *see* Leira, R.
Söhne, M. *see* Kruip, M.J.H.A.
Sørensen, H.T. *see* Nakagawa, S.
Stampfer, M.J. Cardiovascular disease and Alzheimer's disease: common links, 211
Stavem, K., Sandvik, L. & Erikssen, J. Breathlessness, phlegm and mortality: 26 years of follow-up in healthy middle-aged Norwegian men, 332
Stegmayr, B. *see* Eliasson, M.
Stehman-Breen, C. *see* Agarwal, A.K.
Stenlund, H. *see* Norberg, M.
Stettler, C., Suter, Y., Allemann, S., Zwahlen, M., Christ, E.R. & Diem, P. Apolipoprotein B as a long-term predictor of mortality in type 1 diabetes mellitus: a 15-year follow up, 272
Sticherling, C. *see* Schaer, B.A.
Stolz, D. *see* Müller, B.
Ström Möller, C., Zethelius, B., Sundström, J. & Lind, L. Impact of follow-up time and re-measurement of the electrocardiogram and conventional cardiovascular risk factors on their predictive value for myocardial infarction, 22
Süess, E. *see* Müller, B.
Sundström, J. *see* Ström Möller, C.
Suter, Y. *see* Stettler, C.
Suttorp, N. *see* Bauer, T.T.
Svensson, L. *see* Herlitz, J.
Sylvén, C. *see* Rück, A.

Tabrizi, F., Rosenqvist, M., Bergfeldt, L. & Englund, A. Long-term prognosis in patients with bifascicular block – the predictive value of noninvasive and invasive assessment, 31
Takkouche, B. *see* Wiens, M.
Tamm, M. *see* Müller, B.
Testa, E. *see* Testa, R.
Testa, R., Testa, E., Giannini, E., Borro, P., Milazzo, S., Isola, L., Ceppa, P., Lantieri, P.B. & Risso, D. Noninvasive ratio indexes to evaluate fibrosis staging in chronichepatitis C: role of platelet count/spleen diameter ratio index, 142
Tick, L.W. *see* Kruip, M.J.H.A.
Timmers, H.J.L.M., Karperien, M., Hamdy, N.A.T., de Boer, H. & Hermus, A.R.M.M. Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor, 177
Tolfvenstam, T. *see* Broliden, K.
Tornvall, P., Nilsson, T. & Lagerqvist, B. Effects on mortality of abciximab in ST-elevation myocardial infarction treated with percutaneous coronary intervention including stent implantation, 363
Tornvall, P. *see* Jensen, J.
Trip, M.D. *see* Rana, J.S.

Ukkola, O. *see* Pöykkö, S.M.

Varma, N. *see* Agarwal, A.K.
Varpula, M. *see* Saukkonen, K.A.
Vestergaard, P., Rejnmark, L. & Mosekilde, L. Fracture risk associated with the use of morphine and opiates, 76
Vinceneux, P. *see* Fontaine, A.
Virkkunen, I., Kujala, S., Ryynänen, S., Vuori, A., Pettilä, V., Yli-Hankala, A. & Silfvast, T. Bystander mouth-to-mouth ventilation and regurgitation during cardiopulmonary resuscitation, 39
Voipio-Pulkki, L.-M. *see* Saukkonen, K.A.
Vuori, A. *see* Virkkunen, I.

Wang, L.-Y. *see* Huang, J.-F.
Wang, X.B. *see* Giscombe, R.
Wästfelt, M., Fadeel, B. & Henter, J.-I. A journey of hope: lessons learned from studies on rare diseases and orphan drugs, 1

Wehren, L.E. *see* Lips, P.
Weiderpass, E. *see* Lu, M.
Weinehall, L. *see* Norberg, M.
Weissberg, P.L. *see* Iyemere, V.P.
Welte, T. *see* Bauer, T.T.
Wesslau, C. *see* Smith, U.
White, C.M. *see* Henyan, N.N.
Wiens, M., Etminan, M., Gill, S.S. & Takkouche, B. Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies, 350
Wiggers, H. *see* Nørrelund, H.
Wiklund, O. *see* Smith, U.
Wiklund, O. Response by authors, 594
Wikstrand, J. *see* Behre, C.J.
Wisten, A. *see* Herlitz, J.

Ye, W. *see* Lu, M.
Yli-Hankala, A. *see* Virkkunen, I.
Yu, M.-L. *see* Huang, J.-F.

Zanchetta, M. *see* Cesari, M.
Zethelius, B. *see* Ström Möller, C.
Zwahlen, M. *see* Stettler, C.
Zwinderman, A.H. *see* Rana, J.S.

Keyword index

abciximab, 363
acute
  encephalopathy, 164
  heart failure, 1
  stroke, 343
adiponectin, 125, 238, 474
albumin, 62
alcohol, 211
all-cause mortality, 31
Alzheimer's, 211
aminopyrine breath test, 142
anaemia, 577
angina pectoris, 537
angiogenesis, 517
angioplasty, 118
antihypertensive, 350
antipsychotics, 451
anti-tumour, 517
apolipoproteins, 22, 272
ascitis, 62
aseptic menin-gitis, 164
atherosclerosis, 43, 238

B19, 285
behavioural medicine, 388
bifascicular block, 31
bile acids, 530
biomarker, 568
β-blocker, 350
blocker, 350
blood–brain barrier, 493
body mass index, 142, 263
brain cholesterol, 493

calcification, 192
calcium-sensing receptor, 177
cancer, 103
carcinoid, 545
cardiac
  arrest, 39, 435
  electrophysiology, 467
cardiovascular, 134, 211
  death, 537
  disease, 560
  disease prevention, 305
  risk factors, 272
case–control study, 451
CBFA1, 192
cholesterol, 53, 305, 530, 551
cholesteryl ester transfer protein, 151
chronic
  hepatitis C, 142
  kidney disease, 577
cinacalcet, 177
cirrhosis, 62
clinical
  examination, 255, 459
  management, 285
coagulation, 459
cohort, 551
cohort study, 332, 442
collagen disease, 429
community-acquired pneumonia, 93
computed tomography, 459, 545
coronary, 134
  artery disease, 151, 474
  heart disease, 231
cranial pachymeningitis, 164
C-reactive protein, 320
creatinine clearance, 537
critical illness, 586
CYP46, 493
cytokines, 343

darbepoetin alfa, 577
diabetes, 211, 409
diagnosis, 160, 285
differentiation, 192
diuretic, 350
diurnalrhythm, 530
dyspnoea, 332
dysrhythmia, 467

early diagnosis, 399
Ebola, 399
electrocardiogram, 1, 22
emerging diseases, 399
endocrinology, 177
endotoxaemia, 509
enterohepatic circulation, 530
epidemiology, 53, 134, 168, 231, 245, 255, 451, 560
excess mortality, 103

familial
  hemophagocytic lymphohistio-cytosis, 1
  hypocalciuric hyper-calcaemia, 177
fibrinolysis, 320
fitness, 332
forced
  expiratory volume, 560
  vital capacity, 560
fracture, 76, 350
FXR, 530

gastric cancer, 484
glucose metabolism, 11, 263

27-hydroxy cholesterol, 493
H5N1 flu, 399
haemoglobin, 577
heart failure, 11
heart rate variability, 377
hepatitis, 255
HER-2 overexpression, 484
hereditary type I tyrosinemia, 1
hormones, 43
hospital mortality, 586
hospitalization – mortality, 93
hypertension, 474
hyperthermia, 343

idiopathic interstitial pneumonia, 429
imaging, 517
immunotherapy, 509
implantable cardioverter-defibrillator, 88
inadequacy, 245
inappropriate ICD therapy, 88
incidence, 134
infectious disease, 509
inflammation, 377, 509
insulin resistance, 320, 474
intensive care units, 586
internal
  carotid artery, 238
  medicine, 369
interstitial lung disease, 429
intervention, 369
intravenous immunoglobulin, 164
iodine, 69

KL-6, 429

length of stay, 586
leptin, 320
lipid metabolism, 11, 53, 530
liver fibrosis, 142
liver function, 142
longitudinal studies, 22
low
  back pain, 160
  density lipoprotein receptor, 305
  molecular-weight heparin, 168
lymphocytes, 224

meta-analysis, 350
microalbuminuria, 231
MONICA, 551
morphine, 76
mortality, 1, 272, 332
mouth-to-mouth ventilation, 39
muscle metabolism, 11
myocardial
  infarction, 451, 537
    and risk factors, 22
  ischaemia, 320

natriuretic peptides, 568
nephropathy, 255
noradre-naline, 62
NT-proBNP, 125

obesity, 388, 442, 551
opiate, 76
oral therapy, 125
orphan drugs, 1
osteoporotic, 245
outpatient clinic, 88
oxysterols, 493

paracentesis, 62
parathyroid, 177
  hormone, 177
parvovirus, 285
pathogenesis, 285
patient advocacy groups, 1
PCI, 363
peripheral vascular diseases, 151
personalized therapy, 484

© 2006 Blackwell Publishing Ltd

phenotype, 192, 224
phlegm, 332
platelet count/spleen diameter ratio, 142
pneumonia, 568
population-attributable risk, 134
positron emission tomography, 545
postmenopausal, 245
pravastatin, 151
pregnancy, 285
prehospital, 39
primary care, 168, 388
prognosis, 31, 93, 377, 568
  young adults, 435
prognostic factor, 429
prophylaxis, 168
prospective randomized trial, 369
proton ion beam, 484
pulmonary embolism, 459

quality of life, 586

rare diseases, 1
recommendation, 369
regurgitation, 39
relative survival prognosis, 103
renal failure, 231
respiratory
  symptoms, 332
  tract infections, 568
restenosis, 118
restriction fragment length
  polymorphism, 151
resuscitation, 39
revasculari-zation, 118
review, 399
right bundle branch block, 1
risk, 76, 442
  factors, 43, 211, 263, 377

24S-hydroxy-cholesterol, 493
sepsis, 509
severe
  acute respiratory syndrome, 399
  combined immunodeficiency, 1
severity, 93
smoking, 134, 551
smooth muscle cells, 192
socioeconomy, 551
soluble markers, 517
statins, 305
STEMI, 363
stent, 118
stroke, 164, 231, 442
sudden cardiac death, 31
survival, 103
  analysis, 103

T-cell receptor, 224
thiazide, 350
thiazolidinediones, 125
thromboprophylaxis, 369
thyroid
  diseases, 53
  gland, 69
transcription factors, 192
trastuzumab, 484
triglycerides, 53
tuberculosis, 160
type 1 diabetes mellitus, 272
type 2 diabetes, 125
  diabetes mellitus, 263

ultrasound, 238

vaccines, 399
vascular disease, 409
venous thromboembolism incidence, 168
vitamin D, 245

Wegener's granulomatosis, 224
weight loss, 388
West-Nile, 399
women, 238, 320

X-ray fluorescence, 69

zoonosis, 399

Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin 151
P. Marschang, A. Sandhofer, A. Ritsch, I. Fišer, E. Kvas & J. R. Patsch

Spinal tuberculosis: overlooked? 160
S. Abou-Raya & A. Abou-Raya

Intravenous immunoglobulin-associated cranial pachymeningitis 164
I. Marie, F. Hervé, L. Lahaxe, S. Robaday, E. Gerardin & H. Levesque

A prospective observational study of a cohort of outpatients with an acute medical event and reduced mobility: incidence of symptomatic thromboembolism and description of thromboprophylaxis practices 168
J.-L. Bosson, D. Pouchain & J.-F. Bergmann for The ETAPE Study Group

CASE REPORT

Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a *de novo* inactivating mutation of the calcium-sensing receptor 177
H. J. L. M. Timmers, M. Karperien, N. A. T. Hamdy, H. de Boer & A. R. M. M. Hermus

LETTER TO THE EDITOR

Lipoprotein (a) and risk of cardiovascular disease in patients with metabolic syndrome in a population of familial hypercholesterolaemia 183
J. S. Rana, A. C. Jansen, A. H. Zwinderman, E. S. van Aalst-Cohen, J. W. Jukema, M. D. Trip & J. J. P. Kastelein

ERRATUM 186

NO. 3, September 2006

Effector memory T cells as driving force of granuloma formation and autoimmunity in Wegener's granulomatosis 187
P. Lamprecht, E. Csernok & W. L. Gross

REVIEW ARTICLES

Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification 192
V. P. Iyemere, D. Proudfoot, P. L. Weissberg & C. M. Shanahan

Cardiovascular disease and Alzheimer's disease: common links 211
M. J. Stampfer

ORIGINAL ARTICLES

Characterization of the expanded T-cell populations in patients with Wegener's granulomatosis 224
R. Giscombe, X. B. Wang, M. Kakoulidou & A. K. Lefvert

Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases 231
K. P. Klausen, H. Scharling & J. S. Jensen

Are serum adiponectin concentrations in a population sample of 64-year-old Caucasian women with varying glucose tolerance associated with ultrasound-assessed atherosclerosis? 238
C. J. Behre, G. Brohall, J. Hulthe, J. Wikstrand & B. Fagerberg

The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation 245
P. Lips, D. Hosking, K. Lippuner, J. M. Norquist, L. E. Wehren, G. Maalouf, S. Ragi-Eis & J. Chandler

Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? 255
J.-F. Huang, W.-L. Chuang, C.-Y. Dai, C.-K. Ho, S.-J. Hwang, S.-C. Chen, Z.-Y. Lin, L.-Y. Wang, W.-Y. Chang & M.-L. Yu

A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed 263
M. Norberg, J. W. Eriksson, B. Lindahl, C. Andersson, O. Rolandsson, H. Stenlund & L. Weinehall

Apolipoprotein B as a long-term predictor of mortality in type 1 diabetes mellitus: a 15-year follow up 272
C. Stettler, Y. Suter, S. Allemann, M. Zwahlen, E. R. Christ & P. Diem

LETTER TO THE EDITOR

Randomized trials are also essential for device therapy 281
A. Rück & C. Sylvén

Randomized trials are also essential for device therapy: reply 282
P. H. Loh, A. S. Rigby & J. G. F. Cleland

NO. 4, October 2006

REVIEW ARTICLES

Clinical aspects of parvovirus B19 infection 285
K. Broliden, T. Tolfvenstam & O. Norbeck

Who should receive a statin these days? Lessons from recent clinical trials 305
J. Shepherd

ORIGINAL ARTICLES

Cognitive-behavioural stress management does not improve biological cardiovascular risk indicators in women with ischaemic heart disease: a randomized-controlled trial 320
M. Claesson, L. S. Birgander, J.-H. Jansson, B. Lindahl, G. Burell, K. Asplund & C. Mattsson

Breathlessness, phlegm and mortality: 26 years of follow-up in healthy middle-aged Norwegian men 332
K. Stavem, L. Sandvik & J. Erikssen

Hyperthermia is a surrogate marker of inflammation-mediated cause of brain damage in acute ischaemic stroke 343
R. Leira, M. Rodríguez-Yáñez, M. Castellanos, M. Blanco, F. Nombela, T. Sobrino, I. Lizasoain, A. Dávalos & J. Castillo

Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies 350
M. Wiens, M. Etminan, S. S. Gill & B. Takkouche

Effects on mortality of abciximab in ST-elevation myocardial infarction treated with percutaneous coronary intervention including stent implantation 363
P. Tornvall, T. Nilsson & B. Lagerqvist

Effectiveness of written guidelines on the appropriateness of thromboprophylaxis prescriptions for medical patients: a prospective randomized study 369
A. Fontaine, I. Mahé, J. F. Bergmann, J. N. Fiessinger, R. Dhote, P. Cohen & P. Vinceneux

C-reactive protein, heart rate variability and prognosis in community subjects with no apparent heart disease 377
A. Sajadieh, O. W. Nielsen, V. Rasmussen, H. O. Hein & J. F. Hansen

Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat 388
W. S. C. Poston, C. K. Haddock, M. M. Pinkston, P. Pace, R. S. Reeves, N. Karakoc, P. Jones & J. P. Foreyt

NO. 5, November 2006

REVIEW ARTICLES

Zoonotic viral diseases and the frontier of early diagnosis, control and prevention 399
J. L. Heeney

Pathogenesis and treatment of diabetic vascular disease – illustrated by two cases 409
U. Smith, M. Laakso, B. Eliasson, C. Wesslau, J. Borén, O. Wiklund & S. Attvall

ORIGINAL ARTICLES

Right bundle branch block and long-term mortality in patients with acute congestive heart failure 421
C. Mueller, K. Laule-Kilian, T. Klima, T. Breidthardt, W. Hochholzer, A. P. Perruchoud & M. Christ

Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases 429
H. Satoh, K. Kurishima, H. Ishikawa & M. Ohtsuka

Characteristics and outcome amongst young adults suffering from out-of-hospital cardiac arrest in whom cardiopulmonary resuscitation is attempted 435
J. Herlitz, L. Svensson, J. Silfverstolpe, K.-A. Ängquist, A. Wisten, J. Engdahl & S. Holmberg

Prospective study of body size and risk for stroke amongst women below age 60 442
M. Lu, W. Ye, H.-O. Adami & E. Weiderpass

Antipsychotics and risk of first-time hospitalization for myocardial infarction: a population-based case-control study 451
S. Nakagawa, L. Pedersen, M. L. Olsen, P. B. Mortensen, H. T. Sørensen & S. P. Johnsen

A simple diagnostic strategy in hospitalized patients with clinically suspected pulmonary embolism 459
M. J. H. A. Kruip, M. Söhne, M. Nijkeuter, H. M. Kwakkel-van Erp, L. W. Tick, S. J. M. Halkes, M. H. Prins, M. H. H. Kramer, M. V. Huisman, H. R. Büller & F. W. G. Leebeek on behalf of the Christopher study investigators

The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death 467
N. N. Henyan, C. M. White, E. L. Gillespie, K. Smith, C. I. Coleman & J. Kluger

Low plasma adiponectin is associated with coronary artery disease but not with hypertension in high-risk nondiabetic patients 474
M. Cesari, A. C. Pessina, M. Zanchetta, R. De Toni, A. Avogaro, L. Pedon, F. Dorigatti, G. Maiolino & G. P. Rossi

CASE REPORT

HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer 484
T. Inui, A. Asakawa, Y. Morita, S. Mizuno, T. Natori, A. Kawaguchi, M. Murakami, Y. Hishikawa & A. Inui

LETTER TO THE EDITOR

Efficacy or effectiveness? 488
E. Ernst & M. H. Pittler

Erratum 491

NO. 6, December 2006

REVIEW ARTICLES

Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain 493
I. Björkhem

Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis 509
A. Norrby-Teglund, K. N. Haque & L. Hammarström

The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis 517
J. Drevs & V. Schneider

RAPID COMMUNICATION

Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man 530
T. Lundåsen, C. Gälman, B. Angelin & M. Rudling

ORIGINAL ARTICLES

Prognostic implications of renal dysfunction in patients with stable angina pectoris 537
T. Almquist, L. Forslund, N. Rehnqvist & P. Hjemdahl

Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours 545
S. Krüger, A. K. Buck, N. M. Blumstein, S. Pauls, H. Schelzig, C. Kropf, C. Schumann, F. M. Mottaghy, V. Hombach & S. N. Reske

Time trends in population cholesterol levels 1986–2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study 551
M. Eliasson, U. Janlert, J.-H. Jansson & B. Stegmayr

Reduced lung function predicts increased fatality in future cardiac events. a population-based study 560
G. Engström, B. Hedblad & L. Janzon

Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections 568
B. Müller, E. Süess, P. Schuetz, C. Müller, R. Bingisser, A. Bergmann, D. Stolz, M. Tamm, N. G. Morgenthaler & M. Christ-Crain

An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis 577
A. K. Agarwal, M. R. Silver, J. E. Reed, R. K. Dhingra, W. Liu, N. Varma & C. Stehman-Breen

The effect of emergency department delay on outcome in critically ill medical patients: evaluation using hospital mortality and quality of life at 6 months 586
K. A. Saukkonen, M. Varpula, P. Räsänen, R. P. Roine, L.-M. Voipio-Pulkki & V. Pettilä

LETTERS TO THE EDITOR

Statin treatment, reduced T-cell content of atherosclerotic plaques and cancer 592
L. Mascitelli & F. Pezzetta

Response by authors 594
O. Wiklund

Gains and losses during anticoagulation treatment in patients with mechanical heart valves 595
G. S. Filippatos, G. Gavrielatos & D. T. Kremastinos

Bleeding in patients with mechanical heart valves on warfarin: impact of target INR and of comorbidity 596
A. M. Njaastad & U. Abildgaard

Acknowledgement to Reviewers 597

INDEXES

Author index 601

Keyword index 606